T-cell prolymphocytic leukemia.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy.
• T-PLL is characterized by aggressive clinical course and poor response to chemotherapy.
• Median survival for T-PLL patients is historically short.

Purpose of the Study:

• To review the current understanding of T-cell prolymphocytic leukemia.
• To discuss novel therapeutic approaches and their impact on patient outcomes.
• To highlight the role of allogeneic hematopoietic progenitor-cell transplantation in T-PLL management.

Main Methods:

• Review of existing literature on T-cell prolymphocytic leukemia.
• Analysis of treatment outcomes with purine analogs and alemtuzumab.
• Evaluation of hematopoietic progenitor-cell transplantation as a curative option.

Main Results:

• Purine analogs and alemtuzumab have improved response rates and survival in T-PLL.
• Responses to current treatments are often transient.
• Allogeneic hematopoietic progenitor-cell transplantation is the only potentially curative treatment for T-PLL.

Conclusions:

• While new therapies improve outcomes, T-PLL remains a challenging malignancy.
• Allogeneic stem cell transplantation offers the only curative potential for T-PLL.
• Exploring nonmyeloablative transplantation is crucial for older T-PLL patients.